Challenges in Myelodysplastic Syndromes: Raising Awareness and Promoting New Insight in Therapeutic Options

Abstract

References

Mufti

, List

A.F.

, Gore

S.D.

. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2003: 176–199.

Greenberg

. The myelodysplastic syndromes. In: Hoffman

, Benz

E.J.

, Shattil

S.J.

, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000: 1106–1129.

NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. v2.2008. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed July 15, 2008.

The Myelodysplastic Syndromes Foundation. http://www.mdsfoundation.org. Accessed July 15, 2008.

Fenaux

, Mufti

G.J.

, Santini

. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007; 110: 250a. Abstract 817.

Kantarjian

H.M.

, O'Brien

, Huang

. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007; 109(6): 1133–1137.